Sirolimus as frontline therapy for PTEN-mutated histiocytic sarcoma

Karan L Chohan; Jithma P Abeykoon; Jason R Young; W Oliver Tobin; Mathew J Koster; Mithun V Shah; Jay H Ryu; Robert Vassallo; Karen L Rech; Aishwarya Ravindran; Gaurav Goyal; Ronald S Go; N Nora Bennani

doi:10.3324/haematol.2022.282207

Sirolimus as frontline therapy for PTEN-mutated histiocytic sarcoma

Haematologica. 2023 Jun 1;108(6):1702-1706. doi: 10.3324/haematol.2022.282207.

Authors

Affiliations

¹ Department of Medicine, Mayo Clinic, Rochester, MN.
² Division of Hematology, Mayo Clinic, Rochester, MN.
³ Department of Radiology, Mayo Clinic, Jacksonville, FL.
⁴ Department of Neurology, Mayo Clinic, Rochester, MN.
⁵ Division of Rheumatology, Mayo Clinic, Rochester, MN.
⁶ Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN.
⁷ Division of Hematopathology, Mayo Clinic, Rochester, MN.
⁸ Department of Laboratory Medicine-Hematopathology, Department of Pathology, University of Alabama, Birmingham, AL.
⁹ Division of Hematology-Oncology, University of Alabama at Birmingham, Birmingham, AL.
¹⁰ Division of Hematology, Mayo Clinic, Rochester, MN. bennani.nora@mayo.edu.

No abstract available

Publication types

Case Reports

MeSH terms

Histiocytic Sarcoma* / drug therapy
Histiocytic Sarcoma* / genetics
Humans
PTEN Phosphohydrolase / genetics
Sirolimus / therapeutic use

Substances

Sirolimus
PTEN protein, human
PTEN Phosphohydrolase

Grants and funding

Funding: NNB gratefully recognizes support from the K12 Paul Calabresi Program in Clinical/Translational Research at Mayo Clinic (award N 2K12CA090628-21). NNB, JPA, and GG are supported in part by the University of Iowa/Mayo Clinic Lymphoma SPORE CA97422. KLR is supported by the Department of Laboratory Medicine and Pathology and GG is supported by the Walter B. Frommeyer, Jr., Fellowship Award in Investigative Medicine, University of Alabama at Birmingham.